Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-Label Study of YL202 in Advanced Solid Tumors
ChiCTR2500105373Phase 2Recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of YL202 in non-small cell lung cancer (NSCLC), Pulmonary squamous cell carcinoma, breast cancer and 10 more, sponsored by Jilin Provincial Cancer Hospital. Primary endpoints: Pharmacokinetic parameters, Anti-drug antibody (ADA) incidence and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
YL202
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinomabreast cancerhead and neck squamous cell carcinoma (HNSCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500105373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105373.